The effect of chronic DOAC treatment on clinical outcomes of hospitalized patients with COVID-19.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
25
03
2021
accepted:
24
05
2021
pubmed:
10
6
2021
medline:
18
8
2021
entrez:
9
6
2021
Statut:
ppublish
Résumé
Recent findings indicate that thrombosis is one of the underlying pathophysiology and complication of COVID-19 infection. Therefore, the prognosis of the disease may be more favourable in people who were under oral anticoagulant treatment before the COVID-19 diagnosis. This study aims to evaluate the effects of chronic DOAC use on ICU admission and mortality in hospitalized patients due to COVID-19 infection. Between 1 September and 30 November 2020, 2760 patients hospitalized in our hospital due to COVID-19 were screened. A total of 1710 patients who met the inclusion criteria were included in the study. The patients were divided into two groups as those who use DOAC due to any cardiovascular disease before the COVID-19 infection and those who do not. Seventy-nine patients were enrolled in the DOAC group and 1631 patients in the non-DOAC group. Median age of all study patient was 62 (52-71 IQR) and 860 (50.5%) of them were female. The need for intensive care, in-hospital stay, and mechanical ventilation were observed at higher rates in the DOAC group. Mortality was observed in 23 patients (29%) in the DOAC group, and it was statistically higher in the DOAC group (P = .002). In the multivariable analysis, age (OR: 1.047, CI: 1.02-1.06, P < .001), male gender (OR: 1.8, CI: 1.3-2.7, P = .02), lymphocyte count (OR: 0.45, CI: 0.30-0.69, P < .001), procalcitonin (OR: 1.12, CI: 1.02-1.23, P = .015), SaO Our study showed that the use of DOAC prior to hospitalization had no protective effect on in-hospital mortality and intensive care need in hospitalized COVID-19 patients.
Sections du résumé
BACKGROUND
BACKGROUND
Recent findings indicate that thrombosis is one of the underlying pathophysiology and complication of COVID-19 infection. Therefore, the prognosis of the disease may be more favourable in people who were under oral anticoagulant treatment before the COVID-19 diagnosis. This study aims to evaluate the effects of chronic DOAC use on ICU admission and mortality in hospitalized patients due to COVID-19 infection.
METHOD
METHODS
Between 1 September and 30 November 2020, 2760 patients hospitalized in our hospital due to COVID-19 were screened. A total of 1710 patients who met the inclusion criteria were included in the study. The patients were divided into two groups as those who use DOAC due to any cardiovascular disease before the COVID-19 infection and those who do not.
RESULTS
RESULTS
Seventy-nine patients were enrolled in the DOAC group and 1631 patients in the non-DOAC group. Median age of all study patient was 62 (52-71 IQR) and 860 (50.5%) of them were female. The need for intensive care, in-hospital stay, and mechanical ventilation were observed at higher rates in the DOAC group. Mortality was observed in 23 patients (29%) in the DOAC group, and it was statistically higher in the DOAC group (P = .002). In the multivariable analysis, age (OR: 1.047, CI: 1.02-1.06, P < .001), male gender (OR: 1.8, CI: 1.3-2.7, P = .02), lymphocyte count (OR: 0.45, CI: 0.30-0.69, P < .001), procalcitonin (OR: 1.12, CI: 1.02-1.23, P = .015), SaO
CONCLUSION
CONCLUSIONS
Our study showed that the use of DOAC prior to hospitalization had no protective effect on in-hospital mortality and intensive care need in hospitalized COVID-19 patients.
Identifiants
pubmed: 34107130
doi: 10.1111/ijcp.14467
pmc: PMC8237002
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14467Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
Clin Immunol. 2020 Aug;217:108487
pubmed: 32479986
Int J Cardiol. 2021 Jan 15;323:276-280
pubmed: 32911000
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Crit Care. 2015 Aug 18;19:287
pubmed: 26283414
Ann Rheum Dis. 2020 Nov 3;:
pubmed: 33144307
J Intern Med. 2021 Mar;289(3):420-421
pubmed: 33423337
J Thromb Haemost. 2020 Jun;18(6):1517-1519
pubmed: 32294295
Eur J Intern Med. 2020 Jul;77:158-160
pubmed: 32564905
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Blood. 2020 Jul 2;136(1):144-147
pubmed: 32462179
Inflamm Res. 2020 Dec;69(12):1181-1189
pubmed: 32918567
Aging (Albany NY). 2020 Dec 31;13(1):27-60
pubmed: 33472167
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Thromb Res. 2020 Dec;196:27-30
pubmed: 32823173
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
PLoS Med. 2020 Sep 10;17(9):e1003321
pubmed: 32911500
Int J Clin Pract. 2021 Sep;75(9):e14467
pubmed: 34107130
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
J Intern Med. 2021 Mar;289(3):411-419
pubmed: 33258156
Eur J Clin Invest. 2021 Jan;51(1):e13436
pubmed: 33080051
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
Lancet Haematol. 2020 Jun;7(6):e438-e440
pubmed: 32407672
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Br J Haematol. 2020 Aug;190(4):e192-e195
pubmed: 32584423